Cognition Therapeutics Achieves FDA Design Clarity for Zervimesine Phase 3 Study in DLB Psychosis

A registrational study alignment with FDA on zervimesine's Phase 3 design moves Cognition Therapeutics closer to a mid-2027 trial initiation in dementia with Lewy bodies (DLB) psychosis, a milestone that will trigger concrete CMO selection and manufacturing scale-up decisions well before the first patient is dosed.

The Purchase, N.Y.-based company confirmed it held a planned meeting with FDA to discuss the registrational study design for DLB psychosis. Endpoint alignment is still pending, and Cognition has indicated it will provide a timing update once that agreement is reached. The Phase 3 programme will use an improved tablet composition of zervimesine (CT1812), a once-daily oral investigational agent, meaning any contract manufacturing organisation engaged for supply will need to qualify the revised formulation under 21 CFR Part 211 before pivotal-batch production can begin.

On the intellectual property front, Cognition received a Notice of Allowance for a patent covering composition of matter, production process, and therapeutic method for a polymorphic crystalline form of zervimesine in both Alzheimer's disease and DLB. Once issued, the patent extends protection through 2045 before patent-term extension, a coverage horizon that strengthens the commercial rationale for investing in dedicated manufacturing infrastructure.

For QA and regulatory leads tracking the programme, the expanded access extension through 2027, funded by a second philanthropic donor, keeps real-world safety and tolerability data accumulating ahead of the registrational study. A Phase 3 design poster was also presented at the Alzheimer's Association International Convention (AAIC), providing public visibility into the proposed study architecture.

Financially, Cognition reported R&D expenses of $5.1 million for Q2 2026, down from $11.5 million in Q2 2025, reflecting reduced contract research organisation activity. Cash, cash equivalents, and restricted cash equivalents stood at $34.8 million as of June 30, 2026, with $21.6 million in remaining obligated grant funds from the National Institute on Aging. The company estimates runway into Q4 2027, broadly aligned with the planned Phase 3 start window.

The endpoint alignment discussion with FDA represents the critical path item; until that closes, CMO qualification timelines and process validation planning for the revised tablet composition remain contingent.

Source: Cognition Therapeutics, Inc. via GlobeNewswire, August 6, 2026.